Bile duct carcinoma
diseaseOn this page
Also known as bile duct cancerbile duct cancer (including cholangiocarcinoma)carcinoma of bile duct
Summary
Bile duct carcinoma (MONDO:0005496) is a cancer and 106 clinical trials. Top therapeutic interventions include cisplatin, tipiracil, and tivozanib. A subtype of bile duct cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 106
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | bile duct carcinoma |
| Mondo ID | MONDO:0005496 |
| EFO | EFO:0005540 |
| DOID | DOID:4897 |
| NCIT | C27814 |
| UMLS | C0740277 |
| MedGen | 152840 |
| GARD | 0024194 |
| Anatomy (UBERON) | UBERON:0002394 |
| Is cancer (heuristic) | yes |
Also known as: bile duct cancer · bile duct cancer (including cholangiocarcinoma) · bile duct carcinoma · carcinoma of bile duct
Disease family
This is a subtype of bile duct cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › biliary tract cancer › bile duct cancer › bile duct carcinoma
Related subtypes (3): intrahepatic bile duct cancer, bile duct sarcoma, malignant tumor of extrahepatic bile duct
Subtypes (4): bile duct carcinoma in situ, extrahepatic bile duct carcinoma, bile duct adenocarcinoma, squamous cell bile duct carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Porfimer Sodium | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cabozantinib, Capecitabine, Cetuximab, Crizotinib, Everolimus, Fluorouracil, Gefitinib, Gemcitabine, Irinotecan, Ixabepilone, Lapatinib, Oxaliplatin, Regorafenib, Selumetinib, Sorafenib, Temoporfin, Trastuzumab.
Clinical trials & evidence
Clinical trials
Clinical trials: 106.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 50 |
| PHASE2 | 24 |
| PHASE1 | 17 |
| PHASE4 | 5 |
| PHASE1/PHASE2 | 4 |
| PHASE3 | 3 |
| PHASE2/PHASE3 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07120295 | PHASE4 | RECRUITING | Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories |
| NCT00280709 | PHASE4 | COMPLETED | Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction |
| NCT01111591 | PHASE4 | UNKNOWN | Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer |
| NCT01256034 | PHASE4 | COMPLETED | Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy |
| NCT01256047 | PHASE4 | COMPLETED | Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy |
| NCT07155525 | PHASE3 | RECRUITING | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas |
| NCT00809081 | PHASE3 | UNKNOWN | Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy |
| NCT01755013 | PHASE2/PHASE3 | UNKNOWN | Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma |
| NCT02591030 | PHASE2/PHASE3 | COMPLETED | Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours |
| NCT02853474 | PHASE3 | COMPLETED | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy |
| NCT03086993 | PHASE2/PHASE3 | UNKNOWN | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma |
| NCT02628067 | PHASE2 | ACTIVE_NOT_RECRUITING | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) |
| NCT04042831 | PHASE2 | ACTIVE_NOT_RECRUITING | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations |
| NCT05286814 | PHASE2 | RECRUITING | PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma |
| NCT05655949 | PHASE2 | RECRUITING | Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio |
| NCT05849480 | PHASE1/PHASE2 | RECRUITING | A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) |
| NCT06048133 | PHASE2 | RECRUITING | Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) |
| NCT06274879 | PHASE2 | RECRUITING | Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer |
| NCT06730581 | PHASE2 | NOT_YET_RECRUITING | Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors |
| NCT07025174 | PHASE2 | RECRUITING | Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer |
| NCT07030140 | PHASE2 | RECRUITING | Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma |
| NCT00356161 | PHASE2 | UNKNOWN | HAI Via Interventionally Implanted Port Catheter Systems |
| NCT00832637 | PHASE2 | TERMINATED | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers |
| NCT01151761 | PHASE2 | TERMINATED | Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation |
| NCT01317069 | PHASE2 | UNKNOWN | A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer |
| NCT01954745 | PHASE2 | COMPLETED | Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma |
| NCT02821754 | PHASE2 | COMPLETED | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) |
| NCT03058289 | PHASE1/PHASE2 | COMPLETED | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 |
| NCT03111732 | PHASE2 | COMPLETED | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) |
| NCT03602079 | PHASE1/PHASE2 | COMPLETED | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene |
| NCT04072445 | PHASE2 | COMPLETED | Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer |
| NCT04076761 | PHASE2 | TERMINATED | Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma |
| NCT04298008 | PHASE2 | UNKNOWN | AZD6738 Plus Durvalumab in Biliary Tract Cancer |
| NCT04298021 | PHASE2 | UNKNOWN | DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer |
| NCT04383210 | PHASE2 | TERMINATED | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors |
| NCT04566133 | PHASE2 | TERMINATED | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). |
| NCT05000294 | PHASE1/PHASE2 | SUSPENDED | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types |
| NCT05712356 | PHASE2 | TERMINATED | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors |
| NCT05911425 | PHASE2 | UNKNOWN | Combined Treatment of Treated Bile Duct Cancer |
| NCT02381561 | PHASE1 | ACTIVE_NOT_RECRUITING | Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 9 |
| TIPIRACIL | 4 | 3 |
| TIVOZANIB | 4 | 2 |
| TRIFLURIDINE | 4 | 2 |
| AFATINIB | 4 | 1 |
| CABOZANTINIB | 4 | 1 |
| FLOXURIDINE | 4 | 1 |
| MELPHALAN | 4 | 1 |
| TREMELIMUMAB | 4 | 1 |
| CERALASERTIB | 3 | 2 |
| SASANLIMAB | 3 | 1 |
| ZIMBERELIMAB | 3 | 1 |
| CDX-1140 | 2 | 1 |
| CERTEPETIDE | 2 | 1 |
| DKN-01 | 2 | 1 |
| QUEMLICLUSTAT | 2 | 1 |
| ROPIDOXURIDINE | 2 | 1 |
| SERIBANTUMAB | 2 | 1 |
| TRASTUZUMAB BOTIDOTIN | 2 | 1 |
| YTTRIUM Y-90 | 2 | 1 |
| CHEMBL3648328 | 0 | 2 |
| CHEMBL4215501 | 0 | 1 |
| CHEMBL4849721 | 0 | 1 |
| CHEMBL5433950 | 0 | 1 |
| EXELIXIS | 0 | 1 |